MedTrace Logo

Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects

NCT03115762 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2017-04-14

No results posted yet for this study

Summary

This trial will investigate the pharmacokinetic,immunogenicity and safety biosimilarity of ASKB1202 compared to bevacizumab sold in China and Europe.

Conditions

  • Healthy

Interventions

BIOLOGICAL

bevacizumab

recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells

BIOLOGICAL

ASKB1202

Sponsors & Collaborators

  • Jiangsu Aosaikang Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2017-07-31
Completion
2017-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03115762 on ClinicalTrials.gov